Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?
May 10, 2023
FORBES
Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.”
Sen. Sanders is sure to call the pharmaceutical executives — who represent Eli Lilly and Company, Novo Nordisk, and Sanofi — greedy, as he has repeatedly during his tenure atop the HELP Committee. This time, though, PBMs will get some heat, too.
Good. PBMs have unscrupulously created an opaque drug pricing system that has yielded riches for them — at the expense of patients and drug companies.
Click to read the full article in Forbes.
Read More